Immunotherapeutic approaches have revolutionized the treatment of multiple cancers and a large diversity of immunomodulation technologies compete now to reach market authorization.
It is accepted that the characteristics of each patient’s tumor microenvironment (TME) before, during and after a treatment have a major influence on therapy response. The challenge for immunotherapies developers is then to map the key biomarkers of this very complex and diverse TME, to link them to the mechanism of action of the investigated drug and leverage this information with the objective of rationalizing and accelerating the pace of clinical programs from early phases to registration.
The TMExplore TM is a unique tissue-based approach, developed by HalioDx, combining different technologies and an in-house immuno-oncology expertise perfectly adapted to the comprehensive characterization of the tumor microenvironment. From one to hundreds of biomarkers, this customizable solution allows to identify precise cell populations, observe gene expression profiling and focus on biomarkers spatial analysis via multiplex IHC technologies. All those parameters can be combined into an Immunogram multimodal analysis, providing a 360 degree view of the tumor microenvironment.
This unique solution can assist biopharma companies to get meaningful insights from their samples used in clinical trials and gain knowledge in drug mechanism of action and its impact on the immune contexture of the tumor.
Jérôme Galon, PhD, Director, Inserm, Cordeliers Research Center, Paris, France
Jérôme Galon is director of research at INSERM (French NIH) and head of the laboratory of Integrative Cancer Immunology, in Paris, France. He is also associate director and co-founder of the European Academy of Tumor Immunology (EATI), board member of the Society for Immunotherapy of Cancer (SITC), co-founder of HalioDx company and the chairman of its scientific council. His work on the comprehensive analysis of the tumor microenvironment led to the concept of cancer immune contexture.
Jérôme Galon pioneered Immunoscore and is the principal investigator of the Worldwide Immunoscore Consortium. He has been consultant and/or served on the scientific advisory board of 28 biotech and pharmaceutical companies. His contributions have been recognized with numerous awards, including the William B Coley Award, USA (2010), the prestigious European Patent Office (EPO, EU) as European Inventor 2019 for his Immunoscore®, the Senior Research Prize Jean Valade from the Fondation de France (2020) and on January 1st 2020, he was appointed Knight of the Legion of Honour by presidential decree.
Jacques Fieschi, PhD, VP, R&D, HalioDx
Jacques Fieschi is in charge of the Research & Development Department of HalioDx that develops tests and methods to grow the pipeline of the Diagnostic and Pharma Business Units of the Company. Previously, he occupied different positions within the Immunodiagnostic branch of Beckman-Coulter, leading the development of several immunoassays, after which he joined QIAGEN Marseille as Head of Program Management. Fieschi received his PhD degree in immunology from Aix-Marseille University.
Who Should Attend?
This webinar will appeal to individuals with the following or related job titles:
- Translational Research / Cancer Research Scientists
- Directors of Immuno-Oncology Programs / Biomarker sciences / Companion Diagnostics / Profiling
- Clinical Trial Managers / Directors / VP
Working in the following research areas:
- Biomarker discovery
- Clinical Trial
What You Will Learn
In this webinar, participants will learn:
• Why gaining insights into the TME and immune contexture of tumors is crucial for deciphering immunotherapies mechanisms of action
• How biomarker evaluation can be defined and set up
• Which type of innovative and customizable technologies can support this evaluation and provide meaningful information
HalioDx is an immuno-oncology diagnostic company providing oncologists and Biopharma with first-in-class immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immunotherapy and combination therapies.
Thanks to the pioneering work of Dr Jérôme Galon, HalioDx provides a unique range of immune scoring solutions – notably with the flagship Immunoscore® assay – allowing the assessment of the immune contexture of tumor, a key determinant of patient outcomes and response to cancer treatments (from preclinical stage to approved therapies).
To address the needs of Biopharmas, HalioDx has developed innovative technologies such as Multiplex Spatial Tissue Analysis (Brightplex®), molecular testing (NGS, Immunosign® Gene Expression Signatures) and customizable solutions such as TMExplore TM to capture the complexity of the Tumor Microenvironment and Immunogram, a platform integrating Immunoscore® assays.
HalioDx has an experienced team of more than 170 employees, CLIA-certified laboratories and compliant facilities in Europe and in the US to develop, manufacture, register and market in vitro diagnostic (IVD) products. The company co-founded the European immunology cluster Marseille Immunopôle (MI).